Journal of Clinical Oncology: TURBO-NSCLC (ascopubs.org/doi/10.1200/JC…) was a multi-institutional cohort study of 317 treatment-naive EGFR or ALK NSCLC pts with Brain Mets who received TKI w/wo up-front SRS. SRS was associated with superior CNS control. Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center

A new multi-institution study from The Pike Lab and colleagues in Journal of Clinical Oncology finds adding up-front stereotactic radiosurgery improved time to CNS progression in patients with brain metastases from EGFR- and ALK-driven non-small cell lung cancer. #NSCLC bit.ly/3WDgwcF

🧠⚡️🫁☢️New in Journal of Clinical Oncology from The Pike Lab Chad Rusthoven: The addition of up-front #radiation #SRS to CNS-penetrant #TKI ⬆️time-to-CNS progression & local control (but not OS) in pts with brain mets from #EGFR #ALK-driven #NSCLC #lungcancer. #lcsm #radonc ascopubs.org/doi/10.1200/JC…

Any role of up-front SRS in lung pts with brain Mets and EGFR or ALK targetable mutations who is receiving the 3th generation TKIs? JCO July 24, 2024 SRS improves time to CNS progression, particularly for lesion > 1 cm OS is similar MDT and personalized approach are crucial.

In view of TURBO-NSCLC study results, would you offer TKIs + SRS in EGFR/ALK+ve NSCLC patients? OncoAlert OncoViews Oncology Brothers ascopubs.org/doi/abs/10.120… #NSCLC #LungCancer #Oncology #TKI #SRS #EGFR #ALK #CancerResearch #TURBONSCStudy

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for #BrainMetastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-#NSCLC): brnw.ch/21wLHQU Tony Wang #lcsm #btsm

What is the optimal integration of SRS and CNS-active TKIs for brain metastases from EGFR & ALK+ NSCLC? New JAMA Oncology clinical evidence summary for this controversial topic The Pike Lab jamanetwork.com/journals/jamao…

I’m pleased to share our summary of the clinical evidence on the use of TKIs and SRS in EGFR or ALK+ NSCLC! We need better biomarkers to select patients for treatment de-escalation. JAMA Oncology Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology jamanetwork.com/journals/jamao…

The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression. ja.ma/3G3SdyM

FRIDAY! Tune in to our podcast for info on NRG-CC009, an active, accruing NRG study comparing hippocampal avoidant WBRT+memantine to SRS in SCLC that has spread to the brain Vinai Gondi Chad Rusthoven Deborah W. Bruner lisa kachnic CRANE Lab Podcast: nrgoncology.org/Podcast